person · Reporting owner

TULLMAN GLEN

Disclosed activity across 3 companies

Tapewire entity: 140602
SEC CIK: 0001213349

Reported relationships

Latest disclosed role at each company.

Company	Last reported as	Report date	Published
Health Assurance Acquisition Corp.HAAC · Entity 122106	Director	November 12, 2020	November 12, 2020
Teladoc Health, Inc.TDOC · Entity 1547	Director	April 01, 2021	April 02, 2021

Disclosed balances

About these balances

Latest available filing per company, not a reconstructed current portfolio. Matching sequences show the last reported balance with all source rows expandable; grouping alone does not establish account ownership. Do not add unresolved positions together. Filings may omit unchanged positions, and amendments may correct only part of an older disclosure. Jointly reported shares are not necessarily this owner's personal holdings.

Health Assurance Acquisition Corp.

Report date November 12, 2020 · Filed November 12, 2020

Security / award	Ownership account	Disclosed shares / units	Disclosure context
Class B common stockSEC Table II · derivative / convertible security	Direct	Not disclosed	Reported balance Holding disclosure · report date 2020-11-12 · row 1 Instrument identity requires review; Table II rows are not merged. 1 source row Row 1 · Balance Not disclosed F1: As described in the issuer's registration statement on Form S-1 (File No. 333-249667), as amended, under the heading "Description of Securities-Alignment Shares", the shares of Class B common stock, par value $0.0001, will convert into shares of Class A common stock, par value $0.0001, pursuant to the performance of publicly traded shares of Class A common stock of the issuer after the consummation of the issuer's initial business combination.

Filing footnotes · ownership attribution and instrument terms

F1: As described in the issuer's registration statement on Form S-1 (File No. 333-249667), as amended, under the heading "Description of Securities-Alignment Shares", the shares of Class B common stock, par value $0.0001, will convert into shares of Class A common stock, par value $0.0001, pursuant to the performance of publicly traded shares of Class A common stock of the issuer after the consummation of the issuer's initial business combination.

Teladoc Health, Inc.

Report date April 01, 2021 · Filed April 02, 2021

Security / award	Ownership account	Disclosed shares / units	Disclosure context
Common StockSEC Table I · non-derivative	Direct	275,793	Ending reported balance After 2021-04-01 transaction · row 8 8 source rows · reconciled sequence Row 1 · 2021-04-01 · Exercise / conversion · Acquired 329,863 · Balance 605,656 F1: The transactions reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan that was adopted by the reporting person on December 14, 2020. Row 2 · 2021-04-01 · Sale · Disposed 60,148 · Balance 545,508 F1: The transactions reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan that was adopted by the reporting person on December 14, 2020. F2: Represents the weighted average price of transactions ranging from $182.29 to $183.28. The reporting person undertakes to provide, upon request by the SEC staff, the issuer or any security holder of the issuer, full information regarding the number of shares sold at each separate price within the ranges set forth in footnotes 2 through 8 to this Form 4. Row 3 · 2021-04-01 · Sale · Disposed 45,089 · Balance 500,419 F1: The transactions reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan that was adopted by the reporting person on December 14, 2020. F3: Represents the weighted average price of transactions ranging from $183.29 to $184.28. Row 4 · 2021-04-01 · Sale · Disposed 44,825 · Balance 455,594 F1: The transactions reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan that was adopted by the reporting person on December 14, 2020. F4: Represents the weighted average price of transactions ranging from $184.29 to $185.28. Row 5 · 2021-04-01 · Sale · Disposed 24,759 · Balance 430,835 F1: The transactions reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan that was adopted by the reporting person on December 14, 2020. F5: Represents the weighted average price of transactions ranging from $185.30 to $186.28. Row 6 · 2021-04-01 · Sale · Disposed 38,977 · Balance 391,858 F1: The transactions reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan that was adopted by the reporting person on December 14, 2020. F6: Represents the weighted average price of transactions ranging from $186.30 to $187.29. Row 7 · 2021-04-01 · Sale · Disposed 98,588 · Balance 293,270 F1: The transactions reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan that was adopted by the reporting person on December 14, 2020. F7: Represents the weighted average price of transactions ranging from $187.30 to $188.29. Row 8 · 2021-04-01 · Sale · Disposed 17,477 · Balance 275,793 F1: The transactions reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan that was adopted by the reporting person on December 14, 2020. F8: Represents the weighted average price of transactions ranging from $188.295 to $189.00.
Stock Option (right to buy)SEC Table II · derivative / convertible security · Conversion / exercise price $5.26 · Expires 2021-04-30	Direct	0	Reported balance After 2021-04-01 transaction · row 11 Instrument identity requires review; Table II rows are not merged. 1 source row Row 11 · 2021-04-01 · Exercise / conversion · Disposed 329,863 · Balance 0 F1: The transactions reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan that was adopted by the reporting person on December 14, 2020. F11: The option vested in full on October 30, 2020.
Common StockSEC Table I · non-derivative	IndirectSee footnote	21,233	Reported balance Holding disclosure · report date 2021-04-01 · row 9 Holding and transaction disclosures are not merged. 1 source row Row 9 · Balance 21,233 F9: The shares are held of record by 7wire Ventures Fund, L.P. The reporting person serves as a Manager of 7wire Management, LLC, the Manager of 7wire Ventures Fund, L.P. The reporting person disclaims beneficial ownership of these securities, and this report shall not be deemed an admission that the reporting person is the beneficial owner of the securities for purposes of Section 16 or for any other purpose.
Common StockSEC Table I · non-derivative	IndirectSee footnote	1,812	Reported balance Holding disclosure · report date 2021-04-01 · row 10 Holding and transaction disclosures are not merged. 1 source row Row 10 · Balance 1,812 F10: The shares are held of record by 7wire Management I, LLC. The reporting person serves as a Manager of 7wire Management, LLC, the Manager of 7wire Management I, LLC. The reporting person disclaims beneficial ownership of these securities, and this report shall not be deemed an admission that the reporting person is the beneficial owner of the securities for purposes of Section 16 or for any other purpose.

Filing footnotes · ownership attribution and instrument terms

F1: The transactions reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan that was adopted by the reporting person on December 14, 2020.

F2: Represents the weighted average price of transactions ranging from $182.29 to $183.28. The reporting person undertakes to provide, upon request by the SEC staff, the issuer or any security holder of the issuer, full information regarding the number of shares sold at each separate price within the ranges set forth in footnotes 2 through 8 to this Form 4.

F3: Represents the weighted average price of transactions ranging from $183.29 to $184.28.

F4: Represents the weighted average price of transactions ranging from $184.29 to $185.28.

F5: Represents the weighted average price of transactions ranging from $185.30 to $186.28.

F6: Represents the weighted average price of transactions ranging from $186.30 to $187.29.

F7: Represents the weighted average price of transactions ranging from $187.30 to $188.29.

F8: Represents the weighted average price of transactions ranging from $188.295 to $189.00.

F9: The shares are held of record by 7wire Ventures Fund, L.P. The reporting person serves as a Manager of 7wire Management, LLC, the Manager of 7wire Ventures Fund, L.P. The reporting person disclaims beneficial ownership of these securities, and this report shall not be deemed an admission that the reporting person is the beneficial owner of the securities for purposes of Section 16 or for any other purpose.

F10: The shares are held of record by 7wire Management I, LLC. The reporting person serves as a Manager of 7wire Management, LLC, the Manager of 7wire Management I, LLC. The reporting person disclaims beneficial ownership of these securities, and this report shall not be deemed an admission that the reporting person is the beneficial owner of the securities for purposes of Section 16 or for any other purpose.

F11: The option vested in full on October 30, 2020.

Past disclosures · reporting ended (1)

No longer tracked through insider filings. These historical balances do not imply present ownership or a zero position.

Livongo Health, Inc.

Report date September 11, 2020 · Filed October 30, 2020

Section 16 reporting ended · disclosed 2020-10-30. Current position is not established by this disclosure.

Security / award	Ownership account	Disclosed shares / units	Disclosure context
Common StockSEC Table I · non-derivative	Direct	0	Ending reported balance After 2020-10-30 transaction · row 11 4 source rows · reconciled sequence Row 1 · 2020-05-05 · Gift · Disposed 19,941 · Balance 927,862 Row 7 · 2020-10-29 · Other · Acquired 37,712 · Balance 965,574 F11: Represents the receipt of shares pursuant to pro rata in-kind distributions by 7wire Ventures LLC - Series Livongo D and 7wire Ventures LLC - Series Livongo E. Row 9 · 2020-10-30 · Other · Acquired 27,105 · Balance 992,679 F14: Represents the receipt of shares pursuant to a pro rata in-kind distribution by 7wire Ventures Fund L.P. Row 11 · 2020-10-30 · Disposition to issuer · Disposed 992,679 · Balance 0 F16: Includes 77,652 restricted stock units ("RSUs"). F17: Pursuant to the Agreement and Plan of Merger (the "Merger Agreement"), dated as of August 5, 2020, by and among the Issuer, Teladoc Health, Inc. ("Teladoc"), and Tempranillo Merger Sub, Inc., a wholly owned subsidiary of Teladoc, each share of the Issuer's common stock was converted into the right to receive 0.5920 of a share of Teladoc common stock and $4.24 in cash, without interest, together with cash in lieu of fractional shares (if any). F18: Pursuant to the Merger Agreement, each outstanding RSU award of the Issuer was converted into a number of RSUs with respect to a number of shares of Teladoc common stock equal to the product of (i) the number of shares of the Issuer's common stock subject to such RSU award immediately prior to the effective time of the merger and (ii) the Equity Award Adjustment Ratio (as defined below) (rounded down to the nearest whole share of Teladoc common stock on an award-by-award basis), subject to the same terms and conditions as were applicable to such Issuer RSU immediately prior to the effective time of the merger (including applicable vesting conditions). F19: The "Equity Award Adjustment Ratio" means the quotient determined by dividing (i) the volume weighted average closing price of the Issuer's common stock on the four trading days ending on October 29, 2020 by (ii) the volume weighted average closing price of Teladoc common stock on the four trading days beginning on October 29, 2020.
Common StockSEC Table I · non-derivative	IndirectSee footnote	12,080	Reported balance After 2020-09-11 transaction · row 2 Account identity is unresolved; indirect or unspecified ownership is not merged. 1 source row Row 2 · 2020-09-11 · Other · Acquired 12,080 · Balance 12,080 F1: Represents the receipt of shares pursuant to a pro rata in-kind distribution by 7wire Ventures Wanxiang Strategic Fund I, LP. F2: The shares are held of record by 7wire Management I, LLC. The reporting person serves as a Manager of 7wire Management, LLC, or 7wire Management, the Manager of 7wire Management I, LLC. The reporting person disclaims beneficial ownership of these securities, and this report shall not be deemed an admission that the reporting person is the beneficial owner of the securities for purposes of Section 16 or for any other purpose.
Common StockSEC Table I · non-derivative	IndirectSee footnote	0	Reported balance After 2020-10-29 transaction · row 3 Account identity is unresolved; indirect or unspecified ownership is not merged. 1 source row Row 3 · 2020-10-29 · Other · Disposed 1,185,097 · Balance 0 F3: Represents a pro rata in-kind distribution by 7wire Ventures, LLC - Series EosHealth without consideration to its partners. F4: The shares were held of record by 7wire Ventures LLC - Series EosHealth. The reporting person serves as a Manager of 7wire Management, the Manager of 7wire Ventures LLC - Series EosHealth. The reporting person disclaims beneficial ownership of these securities, and this report shall not be deemed an admission that the reporting person is the beneficial owner of the securities for purposes of Section 16 or for any other purpose.
Common StockSEC Table I · non-derivative	IndirectSee footnote	0	Reported balance After 2020-10-29 transaction · row 4 Account identity is unresolved; indirect or unspecified ownership is not merged. 1 source row Row 4 · 2020-10-29 · Other · Disposed 109,748 · Balance 0 F5: Represents a pro rata in-kind distribution by 7wire Ventures LLC - Series Livongo C without consideration to its partners. F6: The shares were held of record by 7wire Ventures LLC - Series Livongo C. The reporting person serves as a Manager of 7wire Management, the Manager of 7wire Ventures LLC - Series Livongo C. The reporting person disclaims beneficial ownership of these securities, and this report shall not be deemed an admission that the reporting person is the beneficial owner of the securities for purposes of Section 16 or for any other purpose.
Common StockSEC Table I · non-derivative	IndirectSee footnote	0	Reported balance After 2020-10-29 transaction · row 5 Account identity is unresolved; indirect or unspecified ownership is not merged. 1 source row Row 5 · 2020-10-29 · Other · Disposed 176,361 · Balance 0 F7: Represents a pro rata in-kind distribution by 7wire Ventures LLC - Series Livongo D without consideration to its partners. F8: The shares were held of record by 7wire Ventures LLC - Series Livongo D. The reporting person serves as a Manager of 7wire Management, the Manager of 7wire Ventures LLC - Series Livongo D. The reporting person disclaims beneficial ownership of these securities, and this report shall not be deemed an admission that the reporting person is the beneficial owner of the securities for purposes of Section 16 or for any other purpose.
Common StockSEC Table I · non-derivative	IndirectSee footnote	0	Reported balance After 2020-10-29 transaction · row 6 Account identity is unresolved; indirect or unspecified ownership is not merged. 1 source row Row 6 · 2020-10-29 · Other · Disposed 195,277 · Balance 0 F9: Represents a pro rata in-kind distribution by 7wire Ventures LLC - Series Livongo E without consideration to its partners. F10: The shares were held of record by 7wire Ventures LLC - Series Livongo E. The reporting person serves as a Manager of 7wire Management, the Manager of 7wire Ventures LLC - Series Livongo E. The reporting person disclaims beneficial ownership of these securities, and this report shall not be deemed an admission that the reporting person is the beneficial owner of the securities for purposes of Section 16 or for any other purpose.
Common StockSEC Table I · non-derivative	IndirectSee footnote	35,887	Reported balance After 2020-10-30 transaction · row 8 Account identity is unresolved; indirect or unspecified ownership is not merged. 1 source row Row 8 · 2020-10-30 · Other · Disposed 940,788 · Balance 35,887 F12: Represents a pro rata in-kind distribution by 7wire Ventures Fund, L.P. without consideration to its partners. F13: The shares are held of record by 7wire Ventures Fund, L.P. The reporting person serves as a Manager of 7wire Management, the Manager of 7wire Ventures Fund, L.P. The reporting person disclaims beneficial ownership of these securities, and this report shall not be deemed an admission that the reporting person is the beneficial owner of the securities for purposes of Section 16 or for any other purpose.
Common StockSEC Table I · non-derivative	IndirectSee footnote	185,121	Reported balance After 2020-10-30 transaction · row 10 Account identity is unresolved; indirect or unspecified ownership is not merged. 1 source row Row 10 · 2020-10-30 · Other · Acquired 173,041 · Balance 185,121 F15: Represents the receipt of shares pursuant to pro rata in-kind distributions by 7wire Ventures Fund L.P. and 7wire Ventures Wanxiang Strategic Fund I, LP. F2: The shares are held of record by 7wire Management I, LLC. The reporting person serves as a Manager of 7wire Management, LLC, or 7wire Management, the Manager of 7wire Management I, LLC. The reporting person disclaims beneficial ownership of these securities, and this report shall not be deemed an admission that the reporting person is the beneficial owner of the securities for purposes of Section 16 or for any other purpose.
Common StockSEC Table I · non-derivative	IndirectSee footnote	0	Reported balance After 2020-10-30 transaction · row 12 Account identity is unresolved; indirect or unspecified ownership is not merged. 1 source row Row 12 · 2020-10-30 · Disposition to issuer · Disposed 35,887 · Balance 0 F17: Pursuant to the Agreement and Plan of Merger (the "Merger Agreement"), dated as of August 5, 2020, by and among the Issuer, Teladoc Health, Inc. ("Teladoc"), and Tempranillo Merger Sub, Inc., a wholly owned subsidiary of Teladoc, each share of the Issuer's common stock was converted into the right to receive 0.5920 of a share of Teladoc common stock and $4.24 in cash, without interest, together with cash in lieu of fractional shares (if any). F13: The shares are held of record by 7wire Ventures Fund, L.P. The reporting person serves as a Manager of 7wire Management, the Manager of 7wire Ventures Fund, L.P. The reporting person disclaims beneficial ownership of these securities, and this report shall not be deemed an admission that the reporting person is the beneficial owner of the securities for purposes of Section 16 or for any other purpose.
Common StockSEC Table I · non-derivative	IndirectSee footnote	0	Reported balance After 2020-10-30 transaction · row 13 Account identity is unresolved; indirect or unspecified ownership is not merged. 1 source row Row 13 · 2020-10-30 · Disposition to issuer · Disposed 185,121 · Balance 0 F17: Pursuant to the Agreement and Plan of Merger (the "Merger Agreement"), dated as of August 5, 2020, by and among the Issuer, Teladoc Health, Inc. ("Teladoc"), and Tempranillo Merger Sub, Inc., a wholly owned subsidiary of Teladoc, each share of the Issuer's common stock was converted into the right to receive 0.5920 of a share of Teladoc common stock and $4.24 in cash, without interest, together with cash in lieu of fractional shares (if any). F2: The shares are held of record by 7wire Management I, LLC. The reporting person serves as a Manager of 7wire Management, LLC, or 7wire Management, the Manager of 7wire Management I, LLC. The reporting person disclaims beneficial ownership of these securities, and this report shall not be deemed an admission that the reporting person is the beneficial owner of the securities for purposes of Section 16 or for any other purpose.
Employee Stock Option (right to buy)SEC Table II · derivative / convertible security · Conversion / exercise price $0.74 · Expires 2024-02-12	Direct	0	Reported balance After 2020-10-30 transaction · row 14 Instrument identity requires review; Table II rows are not merged. 1 source row Row 14 · 2020-10-30 · Disposition to issuer · Disposed 297,954 · Balance 0 F19: The "Equity Award Adjustment Ratio" means the quotient determined by dividing (i) the volume weighted average closing price of the Issuer's common stock on the four trading days ending on October 29, 2020 by (ii) the volume weighted average closing price of Teladoc common stock on the four trading days beginning on October 29, 2020. F21: Pursuant to the Merger Agreement, each outstanding stock option of the Issuer, whether vested or unvested, was converted into an option to purchase a number of shares of Teladoc common stock equal to the product of (i) the number of shares of the Issuer's common stock subject to such Issuer stock option immediately prior to the effective time of the merger and (ii) the Equity Award Adjustment Ratio (rounded down to the nearest whole share of Teladoc common stock on an award-by-award basis), with an exercise price equal to the quotient of (x) the exercise price of such Issuer stock option and (y) the Equity Award Adjustment Ratio (rounded up to the nearest whole cent), subject to the same terms and conditions as were applicable to such Issuer stock option immediately prior to the effective time of the merger (including applicable vesting conditions). F20: Shares subject to the option are fully vested and immediately exercisable.
Employee Stock Option (right to buy)SEC Table II · derivative / convertible security · Conversion / exercise price $0.80 · Expires 2025-03-09	Direct	0	Reported balance After 2020-10-30 transaction · row 15 Instrument identity requires review; Table II rows are not merged. 1 source row Row 15 · 2020-10-30 · Disposition to issuer · Disposed 969,169 · Balance 0 F19: The "Equity Award Adjustment Ratio" means the quotient determined by dividing (i) the volume weighted average closing price of the Issuer's common stock on the four trading days ending on October 29, 2020 by (ii) the volume weighted average closing price of Teladoc common stock on the four trading days beginning on October 29, 2020. F21: Pursuant to the Merger Agreement, each outstanding stock option of the Issuer, whether vested or unvested, was converted into an option to purchase a number of shares of Teladoc common stock equal to the product of (i) the number of shares of the Issuer's common stock subject to such Issuer stock option immediately prior to the effective time of the merger and (ii) the Equity Award Adjustment Ratio (rounded down to the nearest whole share of Teladoc common stock on an award-by-award basis), with an exercise price equal to the quotient of (x) the exercise price of such Issuer stock option and (y) the Equity Award Adjustment Ratio (rounded up to the nearest whole cent), subject to the same terms and conditions as were applicable to such Issuer stock option immediately prior to the effective time of the merger (including applicable vesting conditions). F20: Shares subject to the option are fully vested and immediately exercisable.
Employee Stock Option (right to buy)SEC Table II · derivative / convertible security · Conversion / exercise price $1.88 · Expires 2027-04-30	Direct	0	Reported balance After 2020-10-30 transaction · row 16 Instrument identity requires review; Table II rows are not merged. 1 source row Row 16 · 2020-10-30 · Disposition to issuer · Disposed 1,294,722 · Balance 0 F19: The "Equity Award Adjustment Ratio" means the quotient determined by dividing (i) the volume weighted average closing price of the Issuer's common stock on the four trading days ending on October 29, 2020 by (ii) the volume weighted average closing price of Teladoc common stock on the four trading days beginning on October 29, 2020. F21: Pursuant to the Merger Agreement, each outstanding stock option of the Issuer, whether vested or unvested, was converted into an option to purchase a number of shares of Teladoc common stock equal to the product of (i) the number of shares of the Issuer's common stock subject to such Issuer stock option immediately prior to the effective time of the merger and (ii) the Equity Award Adjustment Ratio (rounded down to the nearest whole share of Teladoc common stock on an award-by-award basis), with an exercise price equal to the quotient of (x) the exercise price of such Issuer stock option and (y) the Equity Award Adjustment Ratio (rounded up to the nearest whole cent), subject to the same terms and conditions as were applicable to such Issuer stock option immediately prior to the effective time of the merger (including applicable vesting conditions). F22: One-fourth of the shares subject to the option vested on May 1, 2018 and 1/48 of the shares vest monthly thereafter.
Employee Stock Option (right to buy)SEC Table II · derivative / convertible security · Conversion / exercise price $3.62 · Expires 2028-01-16	Direct	0	Reported balance After 2020-10-30 transaction · row 17 Instrument identity requires review; Table II rows are not merged. 1 source row Row 17 · 2020-10-30 · Disposition to issuer · Disposed 1,040,360 · Balance 0 F19: The "Equity Award Adjustment Ratio" means the quotient determined by dividing (i) the volume weighted average closing price of the Issuer's common stock on the four trading days ending on October 29, 2020 by (ii) the volume weighted average closing price of Teladoc common stock on the four trading days beginning on October 29, 2020. F21: Pursuant to the Merger Agreement, each outstanding stock option of the Issuer, whether vested or unvested, was converted into an option to purchase a number of shares of Teladoc common stock equal to the product of (i) the number of shares of the Issuer's common stock subject to such Issuer stock option immediately prior to the effective time of the merger and (ii) the Equity Award Adjustment Ratio (rounded down to the nearest whole share of Teladoc common stock on an award-by-award basis), with an exercise price equal to the quotient of (x) the exercise price of such Issuer stock option and (y) the Equity Award Adjustment Ratio (rounded up to the nearest whole cent), subject to the same terms and conditions as were applicable to such Issuer stock option immediately prior to the effective time of the merger (including applicable vesting conditions). F23: One-fourth of the shares subject to the option vested on January 17, 2019 and 1/48 of the shares vest monthly thereafter.
Employee Stock Option (right to buy)SEC Table II · derivative / convertible security · Conversion / exercise price $3.62 · Expires 2028-06-18	Direct	0	Reported balance After 2020-10-30 transaction · row 18 Instrument identity requires review; Table II rows are not merged. 1 source row Row 18 · 2020-10-30 · Disposition to issuer · Disposed 166,000 · Balance 0 F19: The "Equity Award Adjustment Ratio" means the quotient determined by dividing (i) the volume weighted average closing price of the Issuer's common stock on the four trading days ending on October 29, 2020 by (ii) the volume weighted average closing price of Teladoc common stock on the four trading days beginning on October 29, 2020. F21: Pursuant to the Merger Agreement, each outstanding stock option of the Issuer, whether vested or unvested, was converted into an option to purchase a number of shares of Teladoc common stock equal to the product of (i) the number of shares of the Issuer's common stock subject to such Issuer stock option immediately prior to the effective time of the merger and (ii) the Equity Award Adjustment Ratio (rounded down to the nearest whole share of Teladoc common stock on an award-by-award basis), with an exercise price equal to the quotient of (x) the exercise price of such Issuer stock option and (y) the Equity Award Adjustment Ratio (rounded up to the nearest whole cent), subject to the same terms and conditions as were applicable to such Issuer stock option immediately prior to the effective time of the merger (including applicable vesting conditions). F24: One-fourth of the shares subject to the option vested on June 19, 2019 and 1/48 of the shares vest monthly thereafter.

Filing footnotes · ownership attribution and instrument terms

F1: Represents the receipt of shares pursuant to a pro rata in-kind distribution by 7wire Ventures Wanxiang Strategic Fund I, LP.

F2: The shares are held of record by 7wire Management I, LLC. The reporting person serves as a Manager of 7wire Management, LLC, or 7wire Management, the Manager of 7wire Management I, LLC. The reporting person disclaims beneficial ownership of these securities, and this report shall not be deemed an admission that the reporting person is the beneficial owner of the securities for purposes of Section 16 or for any other purpose.

F3: Represents a pro rata in-kind distribution by 7wire Ventures, LLC - Series EosHealth without consideration to its partners.

F4: The shares were held of record by 7wire Ventures LLC - Series EosHealth. The reporting person serves as a Manager of 7wire Management, the Manager of 7wire Ventures LLC - Series EosHealth. The reporting person disclaims beneficial ownership of these securities, and this report shall not be deemed an admission that the reporting person is the beneficial owner of the securities for purposes of Section 16 or for any other purpose.

F5: Represents a pro rata in-kind distribution by 7wire Ventures LLC - Series Livongo C without consideration to its partners.

F6: The shares were held of record by 7wire Ventures LLC - Series Livongo C. The reporting person serves as a Manager of 7wire Management, the Manager of 7wire Ventures LLC - Series Livongo C. The reporting person disclaims beneficial ownership of these securities, and this report shall not be deemed an admission that the reporting person is the beneficial owner of the securities for purposes of Section 16 or for any other purpose.

F7: Represents a pro rata in-kind distribution by 7wire Ventures LLC - Series Livongo D without consideration to its partners.

F8: The shares were held of record by 7wire Ventures LLC - Series Livongo D. The reporting person serves as a Manager of 7wire Management, the Manager of 7wire Ventures LLC - Series Livongo D. The reporting person disclaims beneficial ownership of these securities, and this report shall not be deemed an admission that the reporting person is the beneficial owner of the securities for purposes of Section 16 or for any other purpose.

F9: Represents a pro rata in-kind distribution by 7wire Ventures LLC - Series Livongo E without consideration to its partners.

F10: The shares were held of record by 7wire Ventures LLC - Series Livongo E. The reporting person serves as a Manager of 7wire Management, the Manager of 7wire Ventures LLC - Series Livongo E. The reporting person disclaims beneficial ownership of these securities, and this report shall not be deemed an admission that the reporting person is the beneficial owner of the securities for purposes of Section 16 or for any other purpose.

F11: Represents the receipt of shares pursuant to pro rata in-kind distributions by 7wire Ventures LLC - Series Livongo D and 7wire Ventures LLC - Series Livongo E.

F12: Represents a pro rata in-kind distribution by 7wire Ventures Fund, L.P. without consideration to its partners.

F13: The shares are held of record by 7wire Ventures Fund, L.P. The reporting person serves as a Manager of 7wire Management, the Manager of 7wire Ventures Fund, L.P. The reporting person disclaims beneficial ownership of these securities, and this report shall not be deemed an admission that the reporting person is the beneficial owner of the securities for purposes of Section 16 or for any other purpose.

F14: Represents the receipt of shares pursuant to a pro rata in-kind distribution by 7wire Ventures Fund L.P.

F15: Represents the receipt of shares pursuant to pro rata in-kind distributions by 7wire Ventures Fund L.P. and 7wire Ventures Wanxiang Strategic Fund I, LP.

F16: Includes 77,652 restricted stock units ("RSUs").

F17: Pursuant to the Agreement and Plan of Merger (the "Merger Agreement"), dated as of August 5, 2020, by and among the Issuer, Teladoc Health, Inc. ("Teladoc"), and Tempranillo Merger Sub, Inc., a wholly owned subsidiary of Teladoc, each share of the Issuer's common stock was converted into the right to receive 0.5920 of a share of Teladoc common stock and $4.24 in cash, without interest, together with cash in lieu of fractional shares (if any).

F18: Pursuant to the Merger Agreement, each outstanding RSU award of the Issuer was converted into a number of RSUs with respect to a number of shares of Teladoc common stock equal to the product of (i) the number of shares of the Issuer's common stock subject to such RSU award immediately prior to the effective time of the merger and (ii) the Equity Award Adjustment Ratio (as defined below) (rounded down to the nearest whole share of Teladoc common stock on an award-by-award basis), subject to the same terms and conditions as were applicable to such Issuer RSU immediately prior to the effective time of the merger (including applicable vesting conditions).

F19: The "Equity Award Adjustment Ratio" means the quotient determined by dividing (i) the volume weighted average closing price of the Issuer's common stock on the four trading days ending on October 29, 2020 by (ii) the volume weighted average closing price of Teladoc common stock on the four trading days beginning on October 29, 2020.

F20: Shares subject to the option are fully vested and immediately exercisable.

F21: Pursuant to the Merger Agreement, each outstanding stock option of the Issuer, whether vested or unvested, was converted into an option to purchase a number of shares of Teladoc common stock equal to the product of (i) the number of shares of the Issuer's common stock subject to such Issuer stock option immediately prior to the effective time of the merger and (ii) the Equity Award Adjustment Ratio (rounded down to the nearest whole share of Teladoc common stock on an award-by-award basis), with an exercise price equal to the quotient of (x) the exercise price of such Issuer stock option and (y) the Equity Award Adjustment Ratio (rounded up to the nearest whole cent), subject to the same terms and conditions as were applicable to such Issuer stock option immediately prior to the effective time of the merger (including applicable vesting conditions).

F22: One-fourth of the shares subject to the option vested on May 1, 2018 and 1/48 of the shares vest monthly thereafter.

F23: One-fourth of the shares subject to the option vested on January 17, 2019 and 1/48 of the shares vest monthly thereafter.

F24: One-fourth of the shares subject to the option vested on June 19, 2019 and 1/48 of the shares vest monthly thereafter.

Transaction history

JSON API

Purchases/sales include open-market and private transactions. Plan disclosure applies to the filing; individual rows may differ. “Not disclosed” is not “unplanned.”

The cutoff filters transaction history only. Company summaries and owner relationships show the latest available disclosures. Parser corrections can improve historical records.

Transaction date	Company	Activity / security	Shares / units	Reported price	Reported value	Details
April 01, 2021 Filed Apr 2, 2021 19:03 UTC	Teladoc Health, Inc. TDOC · Entity 1547	Exercise / conversionStock Option (right to buy) · Derivative	329,863	$0.00 Strike: $5.26	$0.00	Disclosure SEC source: 0001179110-21-004092 · edgar.xml · derivative · entry 11 TULLMAN GLEN · CIK 0001213349 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 329,863 shares Expires 2021-04-30 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: The transactions reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan that was adopted by the reporting person on December 14, 2020. F11 · derivative.exercise_date: The option vested in full on October 30, 2020. Read SEC document
April 01, 2021 Filed Apr 2, 2021 19:03 UTC	Teladoc Health, Inc. TDOC · Entity 1547	SaleCommon Stock	17,477	$188.45	$3,293,467.25	Disclosure SEC source: 0001179110-21-004092 · edgar.xml · nonDerivative · entry 8 TULLMAN GLEN · CIK 0001213349 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 275,793 F1 · kind: The transactions reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan that was adopted by the reporting person on December 14, 2020. F8 · price: Represents the weighted average price of transactions ranging from $188.295 to $189.00. Read SEC document
April 01, 2021 Filed Apr 2, 2021 19:03 UTC	Teladoc Health, Inc. TDOC · Entity 1547	SaleCommon Stock	98,588	$187.85	$18,520,071.28	Disclosure SEC source: 0001179110-21-004092 · edgar.xml · nonDerivative · entry 7 TULLMAN GLEN · CIK 0001213349 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 293,270 F1 · kind: The transactions reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan that was adopted by the reporting person on December 14, 2020. F7 · price: Represents the weighted average price of transactions ranging from $187.30 to $188.29. Read SEC document
April 01, 2021 Filed Apr 2, 2021 19:03 UTC	Teladoc Health, Inc. TDOC · Entity 1547	SaleCommon Stock	38,977	$186.92	$7,285,760.13	Disclosure SEC source: 0001179110-21-004092 · edgar.xml · nonDerivative · entry 6 TULLMAN GLEN · CIK 0001213349 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 391,858 F1 · kind: The transactions reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan that was adopted by the reporting person on December 14, 2020. F6 · price: Represents the weighted average price of transactions ranging from $186.30 to $187.29. Read SEC document
April 01, 2021 Filed Apr 2, 2021 19:03 UTC	Teladoc Health, Inc. TDOC · Entity 1547	SaleCommon Stock	24,759	$185.80	$4,600,128.12	Disclosure SEC source: 0001179110-21-004092 · edgar.xml · nonDerivative · entry 5 TULLMAN GLEN · CIK 0001213349 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 430,835 F1 · kind: The transactions reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan that was adopted by the reporting person on December 14, 2020. F5 · price: Represents the weighted average price of transactions ranging from $185.30 to $186.28. Read SEC document
April 01, 2021 Filed Apr 2, 2021 19:03 UTC	Teladoc Health, Inc. TDOC · Entity 1547	SaleCommon Stock	44,825	$184.68	$8,278,375.13	Disclosure SEC source: 0001179110-21-004092 · edgar.xml · nonDerivative · entry 4 TULLMAN GLEN · CIK 0001213349 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 455,594 F1 · kind: The transactions reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan that was adopted by the reporting person on December 14, 2020. F4 · price: Represents the weighted average price of transactions ranging from $184.29 to $185.28. Read SEC document
April 01, 2021 Filed Apr 2, 2021 19:03 UTC	Teladoc Health, Inc. TDOC · Entity 1547	SaleCommon Stock	45,089	$183.78	$8,286,627.76	Disclosure SEC source: 0001179110-21-004092 · edgar.xml · nonDerivative · entry 3 TULLMAN GLEN · CIK 0001213349 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 500,419 F1 · kind: The transactions reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan that was adopted by the reporting person on December 14, 2020. F3 · price: Represents the weighted average price of transactions ranging from $183.29 to $184.28. Read SEC document
April 01, 2021 Filed Apr 2, 2021 19:03 UTC	Teladoc Health, Inc. TDOC · Entity 1547	SaleCommon Stock	60,148	$182.78	$10,993,911.59	Disclosure SEC source: 0001179110-21-004092 · edgar.xml · nonDerivative · entry 2 TULLMAN GLEN · CIK 0001213349 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 545,508 F1 · kind: The transactions reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan that was adopted by the reporting person on December 14, 2020. F2 · price: Represents the weighted average price of transactions ranging from $182.29 to $183.28. The reporting person undertakes to provide, upon request by the SEC staff, the issuer or any security holder of the issuer, full information regarding the number of shares sold at each separate price within the ranges set forth in footnotes 2 through 8 to this Form 4. Read SEC document
April 01, 2021 Filed Apr 2, 2021 19:03 UTC	Teladoc Health, Inc. TDOC · Entity 1547	Exercise / conversionCommon Stock	329,863	$5.26	$1,735,079.38	Disclosure SEC source: 0001179110-21-004092 · edgar.xml · nonDerivative · entry 1 TULLMAN GLEN · CIK 0001213349 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 605,656 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: The transactions reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan that was adopted by the reporting person on December 14, 2020. Read SEC document
March 01, 2021 Filed Mar 3, 2021 22:52 UTC	Teladoc Health, Inc. TDOC · Entity 1547	Exercise / conversionStock Option (right to buy) · Derivative	164,931	$0.00 Strike: $5.26	$0.00	Disclosure SEC source: 0001179110-21-002719 · edgar.xml · derivative · entry 5 TULLMAN GLEN · CIK 0001213349 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 329,863 Underlying: Common Stock · 164,931 shares Expires 2021-04-30 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: The transactions reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan that was adopted by the reporting person on December 14, 2020. F3 · derivative.exercise_date: The option vested in full on October 30, 2020. Read SEC document
March 01, 2021 Filed Mar 3, 2021 22:52 UTC	Teladoc Health, Inc. TDOC · Entity 1547	SaleCommon Stock	164,931	$226.06	$37,283,906.03	Disclosure SEC source: 0001179110-21-002719 · edgar.xml · nonDerivative · entry 2 TULLMAN GLEN · CIK 0001213349 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 275,793 F1 · kind: The transactions reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan that was adopted by the reporting person on December 14, 2020. F2 · price: Represents the weighted average price of transactions ranging from $221.22 to $229.75. The reporting person undertakes to provide, upon request by the SEC staff, the issuer or any security holder of the issuer, full information regarding the number of shares sold at each separate price. Read SEC document
March 01, 2021 Filed Mar 3, 2021 22:52 UTC	Teladoc Health, Inc. TDOC · Entity 1547	Exercise / conversionCommon Stock	164,931	$5.26	$867,537.06	Disclosure SEC source: 0001179110-21-002719 · edgar.xml · nonDerivative · entry 1 TULLMAN GLEN · CIK 0001213349 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 440,724 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: The transactions reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan that was adopted by the reporting person on December 14, 2020. Read SEC document
February 01, 2021 Filed Feb 3, 2021 23:03 UTC	Teladoc Health, Inc. TDOC · Entity 1547	Exercise / conversionStock Option (right to buy) · Derivative	164,931	$0.00 Strike: $5.26	$0.00	Disclosure SEC source: 0001179110-21-001277 · edgar.xml · derivative · entry 3 TULLMAN GLEN · CIK 0001213349 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 494,794 Underlying: Common Stock · 164,931 shares Expires 2021-04-30 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F3 · derivative.exercise_date: The option vested in full on October 30, 2020. Read SEC document
February 01, 2021 Filed Feb 3, 2021 23:03 UTC	Teladoc Health, Inc. TDOC · Entity 1547	SaleCommon Stock	164,931	$262.61	$43,312,529.91	Disclosure SEC source: 0001179110-21-001277 · edgar.xml · nonDerivative · entry 2 TULLMAN GLEN · CIK 0001213349 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 275,793 F1 · shares: The sales reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan that was adopted by the reporting person on December 14, 2020. F2 · price: Represents the weighted average price of transactions ranging from $257.01 to $266.64. The reporting person undertakes to provide, upon request by the SEC staff, the issuer or any security holder of the issuer, full information regarding the number of shares sold at each separate price. Read SEC document
February 01, 2021 Filed Feb 3, 2021 23:03 UTC	Teladoc Health, Inc. TDOC · Entity 1547	Exercise / conversionCommon Stock	164,931	$5.26	$867,537.06	Disclosure SEC source: 0001179110-21-001277 · edgar.xml · nonDerivative · entry 1 TULLMAN GLEN · CIK 0001213349 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 440,724 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document
January 14, 2021 Filed Jan 19, 2021 21:04 UTC	Teladoc Health, Inc. TDOC · Entity 1547	Exercise / conversionStock Option (right to buy) · Derivative	164,931	$0.00 Strike: $5.26	$0.00	Disclosure SEC source: 0001179110-21-000672 · edgar.xml · derivative · entry 3 TULLMAN GLEN · CIK 0001213349 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 659,725 Underlying: Common Stock · 164,931 shares Expires 2021-04-30 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F3 · derivative.exercise_date: The option vested in full on October 30, 2020. Read SEC document
January 14, 2021 Filed Jan 19, 2021 21:04 UTC	Teladoc Health, Inc. TDOC · Entity 1547	SaleCommon Stock	164,931	$225.12	$37,129,266.72	Disclosure SEC source: 0001179110-21-000672 · edgar.xml · nonDerivative · entry 2 TULLMAN GLEN · CIK 0001213349 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 275,793 F1 · shares: The sales reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan that was adopted by the reporting person on December 14, 2020. F2 · price: Represents the weighted average price of transactions ranging from $221.81 to $228.97. The reporting person undertakes to provide, upon request by the SEC staff, the issuer or any security holder of the issuer, full information regarding the number of shares sold at each separate price. Read SEC document
January 14, 2021 Filed Jan 19, 2021 21:04 UTC	Teladoc Health, Inc. TDOC · Entity 1547	Exercise / conversionCommon Stock	164,931	$5.26	$867,537.06	Disclosure SEC source: 0001179110-21-000672 · edgar.xml · nonDerivative · entry 1 TULLMAN GLEN · CIK 0001213349 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 440,724 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document
November 19, 2020 Filed Nov 20, 2020 21:43 UTC	Teladoc Health, Inc. TDOC · Entity 1547	GrantRestricted Stock Units · Derivative	1,308	$0.00	$0.00	Disclosure SEC source: 0001179110-20-011269 · edgar.xml · derivative · entry 1 TULLMAN GLEN · CIK 0001213349 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 1,308 Underlying: Common Stock · 1,308 shares Expires not disclosed F1 · derivative.exercise_price: Each restricted stock unit represents a contingent right to receive one share of TDOC common stock. F2 · derivative.exercise_date: The restricted stock unit vests in three substantially equal annual installments beginning November 19, 2021. F2 · derivative.expiration_date: The restricted stock unit vests in three substantially equal annual installments beginning November 19, 2021. Read SEC document
October 30, 2020 Filed Oct 30, 2020 17:15 UTC	Livongo Health, Inc. LVGO · Entity 145566	Disposition to issuerEmployee Stock Option (right to buy) · Derivative	166,000	Not disclosed Strike: $3.62	Not disclosed	Disclosure SEC source: 0001639225-20-000060 · wf-form4_160409251194751.xml · derivative · entry 18 TULLMAN GLEN · CIK 0001213349 · Director · Executive Chairman 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 166,000 shares Expires 2028-06-18 F19 · price: The "Equity Award Adjustment Ratio" means the quotient determined by dividing (i) the volume weighted average closing price of the Issuer's common stock on the four trading days ending on October 29, 2020 by (ii) the volume weighted average closing price of Teladoc common stock on the four trading days beginning on October 29, 2020. F21 · price: Pursuant to the Merger Agreement, each outstanding stock option of the Issuer, whether vested or unvested, was converted into an option to purchase a number of shares of Teladoc common stock equal to the product of (i) the number of shares of the Issuer's common stock subject to such Issuer stock option immediately prior to the effective time of the merger and (ii) the Equity Award Adjustment Ratio (rounded down to the nearest whole share of Teladoc common stock on an award-by-award basis), with an exercise price equal to the quotient of (x) the exercise price of such Issuer stock option and (y) the Equity Award Adjustment Ratio (rounded up to the nearest whole cent), subject to the same terms and conditions as were applicable to such Issuer stock option immediately prior to the effective time of the merger (including applicable vesting conditions). F24 · derivative.exercise_date: One-fourth of the shares subject to the option vested on June 19, 2019 and 1/48 of the shares vest monthly thereafter. Read SEC document
October 30, 2020 Filed Oct 30, 2020 17:15 UTC	Livongo Health, Inc. LVGO · Entity 145566	Disposition to issuerEmployee Stock Option (right to buy) · Derivative	1,040,360	Not disclosed Strike: $3.62	Not disclosed	Disclosure SEC source: 0001639225-20-000060 · wf-form4_160409251194751.xml · derivative · entry 17 TULLMAN GLEN · CIK 0001213349 · Director · Executive Chairman 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 1,040,360 shares Expires 2028-01-16 F19 · price: The "Equity Award Adjustment Ratio" means the quotient determined by dividing (i) the volume weighted average closing price of the Issuer's common stock on the four trading days ending on October 29, 2020 by (ii) the volume weighted average closing price of Teladoc common stock on the four trading days beginning on October 29, 2020. F21 · price: Pursuant to the Merger Agreement, each outstanding stock option of the Issuer, whether vested or unvested, was converted into an option to purchase a number of shares of Teladoc common stock equal to the product of (i) the number of shares of the Issuer's common stock subject to such Issuer stock option immediately prior to the effective time of the merger and (ii) the Equity Award Adjustment Ratio (rounded down to the nearest whole share of Teladoc common stock on an award-by-award basis), with an exercise price equal to the quotient of (x) the exercise price of such Issuer stock option and (y) the Equity Award Adjustment Ratio (rounded up to the nearest whole cent), subject to the same terms and conditions as were applicable to such Issuer stock option immediately prior to the effective time of the merger (including applicable vesting conditions). F23 · derivative.exercise_date: One-fourth of the shares subject to the option vested on January 17, 2019 and 1/48 of the shares vest monthly thereafter. Read SEC document
October 30, 2020 Filed Oct 30, 2020 17:15 UTC	Livongo Health, Inc. LVGO · Entity 145566	Disposition to issuerEmployee Stock Option (right to buy) · Derivative	1,294,722	Not disclosed Strike: $1.88	Not disclosed	Disclosure SEC source: 0001639225-20-000060 · wf-form4_160409251194751.xml · derivative · entry 16 TULLMAN GLEN · CIK 0001213349 · Director · Executive Chairman 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 1,294,722 shares Expires 2027-04-30 F19 · price: The "Equity Award Adjustment Ratio" means the quotient determined by dividing (i) the volume weighted average closing price of the Issuer's common stock on the four trading days ending on October 29, 2020 by (ii) the volume weighted average closing price of Teladoc common stock on the four trading days beginning on October 29, 2020. F21 · price: Pursuant to the Merger Agreement, each outstanding stock option of the Issuer, whether vested or unvested, was converted into an option to purchase a number of shares of Teladoc common stock equal to the product of (i) the number of shares of the Issuer's common stock subject to such Issuer stock option immediately prior to the effective time of the merger and (ii) the Equity Award Adjustment Ratio (rounded down to the nearest whole share of Teladoc common stock on an award-by-award basis), with an exercise price equal to the quotient of (x) the exercise price of such Issuer stock option and (y) the Equity Award Adjustment Ratio (rounded up to the nearest whole cent), subject to the same terms and conditions as were applicable to such Issuer stock option immediately prior to the effective time of the merger (including applicable vesting conditions). F22 · derivative.exercise_date: One-fourth of the shares subject to the option vested on May 1, 2018 and 1/48 of the shares vest monthly thereafter. Read SEC document
October 30, 2020 Filed Oct 30, 2020 17:15 UTC	Livongo Health, Inc. LVGO · Entity 145566	Disposition to issuerEmployee Stock Option (right to buy) · Derivative	969,169	Not disclosed Strike: $0.80	Not disclosed	Disclosure SEC source: 0001639225-20-000060 · wf-form4_160409251194751.xml · derivative · entry 15 TULLMAN GLEN · CIK 0001213349 · Director · Executive Chairman 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 969,169 shares Expires 2025-03-09 F19 · price: The "Equity Award Adjustment Ratio" means the quotient determined by dividing (i) the volume weighted average closing price of the Issuer's common stock on the four trading days ending on October 29, 2020 by (ii) the volume weighted average closing price of Teladoc common stock on the four trading days beginning on October 29, 2020. F21 · price: Pursuant to the Merger Agreement, each outstanding stock option of the Issuer, whether vested or unvested, was converted into an option to purchase a number of shares of Teladoc common stock equal to the product of (i) the number of shares of the Issuer's common stock subject to such Issuer stock option immediately prior to the effective time of the merger and (ii) the Equity Award Adjustment Ratio (rounded down to the nearest whole share of Teladoc common stock on an award-by-award basis), with an exercise price equal to the quotient of (x) the exercise price of such Issuer stock option and (y) the Equity Award Adjustment Ratio (rounded up to the nearest whole cent), subject to the same terms and conditions as were applicable to such Issuer stock option immediately prior to the effective time of the merger (including applicable vesting conditions). F20 · derivative.exercise_date: Shares subject to the option are fully vested and immediately exercisable. Read SEC document
October 30, 2020 Filed Oct 30, 2020 17:15 UTC	Livongo Health, Inc. LVGO · Entity 145566	Disposition to issuerEmployee Stock Option (right to buy) · Derivative	297,954	Not disclosed Strike: $0.74	Not disclosed	Disclosure SEC source: 0001639225-20-000060 · wf-form4_160409251194751.xml · derivative · entry 14 TULLMAN GLEN · CIK 0001213349 · Director · Executive Chairman 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 297,954 shares Expires 2024-02-12 F19 · price: The "Equity Award Adjustment Ratio" means the quotient determined by dividing (i) the volume weighted average closing price of the Issuer's common stock on the four trading days ending on October 29, 2020 by (ii) the volume weighted average closing price of Teladoc common stock on the four trading days beginning on October 29, 2020. F21 · price: Pursuant to the Merger Agreement, each outstanding stock option of the Issuer, whether vested or unvested, was converted into an option to purchase a number of shares of Teladoc common stock equal to the product of (i) the number of shares of the Issuer's common stock subject to such Issuer stock option immediately prior to the effective time of the merger and (ii) the Equity Award Adjustment Ratio (rounded down to the nearest whole share of Teladoc common stock on an award-by-award basis), with an exercise price equal to the quotient of (x) the exercise price of such Issuer stock option and (y) the Equity Award Adjustment Ratio (rounded up to the nearest whole cent), subject to the same terms and conditions as were applicable to such Issuer stock option immediately prior to the effective time of the merger (including applicable vesting conditions). F20 · derivative.exercise_date: Shares subject to the option are fully vested and immediately exercisable. Read SEC document
October 30, 2020 Filed Oct 30, 2020 17:15 UTC	Livongo Health, Inc. LVGO · Entity 145566	Disposition to issuerCommon Stock	185,121	Not disclosed	Not disclosed	Disclosure SEC source: 0001639225-20-000060 · wf-form4_160409251194751.xml · nonDerivative · entry 13 TULLMAN GLEN · CIK 0001213349 · Director · Executive Chairman 10b5-1 filing: Not disclosed Ownership: Indirect · See footnote Disclosed balance after: 0 F17 · price: Pursuant to the Agreement and Plan of Merger (the "Merger Agreement"), dated as of August 5, 2020, by and among the Issuer, Teladoc Health, Inc. ("Teladoc"), and Tempranillo Merger Sub, Inc., a wholly owned subsidiary of Teladoc, each share of the Issuer's common stock was converted into the right to receive 0.5920 of a share of Teladoc common stock and $4.24 in cash, without interest, together with cash in lieu of fractional shares (if any). F2 · ownership.nature: The shares are held of record by 7wire Management I, LLC. The reporting person serves as a Manager of 7wire Management, LLC, or 7wire Management, the Manager of 7wire Management I, LLC. The reporting person disclaims beneficial ownership of these securities, and this report shall not be deemed an admission that the reporting person is the beneficial owner of the securities for purposes of Section 16 or for any other purpose. Read SEC document
October 30, 2020 Filed Oct 30, 2020 17:15 UTC	Livongo Health, Inc. LVGO · Entity 145566	Disposition to issuerCommon Stock	35,887	Not disclosed	Not disclosed	Disclosure SEC source: 0001639225-20-000060 · wf-form4_160409251194751.xml · nonDerivative · entry 12 TULLMAN GLEN · CIK 0001213349 · Director · Executive Chairman 10b5-1 filing: Not disclosed Ownership: Indirect · See footnote Disclosed balance after: 0 F17 · price: Pursuant to the Agreement and Plan of Merger (the "Merger Agreement"), dated as of August 5, 2020, by and among the Issuer, Teladoc Health, Inc. ("Teladoc"), and Tempranillo Merger Sub, Inc., a wholly owned subsidiary of Teladoc, each share of the Issuer's common stock was converted into the right to receive 0.5920 of a share of Teladoc common stock and $4.24 in cash, without interest, together with cash in lieu of fractional shares (if any). F13 · ownership.nature: The shares are held of record by 7wire Ventures Fund, L.P. The reporting person serves as a Manager of 7wire Management, the Manager of 7wire Ventures Fund, L.P. The reporting person disclaims beneficial ownership of these securities, and this report shall not be deemed an admission that the reporting person is the beneficial owner of the securities for purposes of Section 16 or for any other purpose. Read SEC document
October 30, 2020 Filed Oct 30, 2020 17:15 UTC	Livongo Health, Inc. LVGO · Entity 145566	Disposition to issuerCommon Stock	992,679	Not disclosed	Not disclosed	Disclosure SEC source: 0001639225-20-000060 · wf-form4_160409251194751.xml · nonDerivative · entry 11 TULLMAN GLEN · CIK 0001213349 · Director · Executive Chairman 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 F16 · shares: Includes 77,652 restricted stock units ("RSUs"). F17 · price: Pursuant to the Agreement and Plan of Merger (the "Merger Agreement"), dated as of August 5, 2020, by and among the Issuer, Teladoc Health, Inc. ("Teladoc"), and Tempranillo Merger Sub, Inc., a wholly owned subsidiary of Teladoc, each share of the Issuer's common stock was converted into the right to receive 0.5920 of a share of Teladoc common stock and $4.24 in cash, without interest, together with cash in lieu of fractional shares (if any). F18 · price: Pursuant to the Merger Agreement, each outstanding RSU award of the Issuer was converted into a number of RSUs with respect to a number of shares of Teladoc common stock equal to the product of (i) the number of shares of the Issuer's common stock subject to such RSU award immediately prior to the effective time of the merger and (ii) the Equity Award Adjustment Ratio (as defined below) (rounded down to the nearest whole share of Teladoc common stock on an award-by-award basis), subject to the same terms and conditions as were applicable to such Issuer RSU immediately prior to the effective time of the merger (including applicable vesting conditions). F19 · price: The "Equity Award Adjustment Ratio" means the quotient determined by dividing (i) the volume weighted average closing price of the Issuer's common stock on the four trading days ending on October 29, 2020 by (ii) the volume weighted average closing price of Teladoc common stock on the four trading days beginning on October 29, 2020. Read SEC document
October 30, 2020 Filed Oct 30, 2020 17:15 UTC	Livongo Health, Inc. LVGO · Entity 145566	OtherCommon Stock	173,041	$0.00	$0.00	Disclosure SEC source: 0001639225-20-000060 · wf-form4_160409251194751.xml · nonDerivative · entry 10 TULLMAN GLEN · CIK 0001213349 · Director · Executive Chairman 10b5-1 filing: Not disclosed Ownership: Indirect · See footnote Disclosed balance after: 185,121 F15 · kind: Represents the receipt of shares pursuant to pro rata in-kind distributions by 7wire Ventures Fund L.P. and 7wire Ventures Wanxiang Strategic Fund I, LP. F2 · ownership.nature: The shares are held of record by 7wire Management I, LLC. The reporting person serves as a Manager of 7wire Management, LLC, or 7wire Management, the Manager of 7wire Management I, LLC. The reporting person disclaims beneficial ownership of these securities, and this report shall not be deemed an admission that the reporting person is the beneficial owner of the securities for purposes of Section 16 or for any other purpose. Read SEC document
October 30, 2020 Filed Oct 30, 2020 17:15 UTC	Livongo Health, Inc. LVGO · Entity 145566	OtherCommon Stock	27,105	$0.00	$0.00	Disclosure SEC source: 0001639225-20-000060 · wf-form4_160409251194751.xml · nonDerivative · entry 9 TULLMAN GLEN · CIK 0001213349 · Director · Executive Chairman 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 992,679 F14 · kind: Represents the receipt of shares pursuant to a pro rata in-kind distribution by 7wire Ventures Fund L.P. Read SEC document
October 30, 2020 Filed Oct 30, 2020 17:15 UTC	Livongo Health, Inc. LVGO · Entity 145566	OtherCommon Stock	940,788	$0.00	$0.00	Disclosure SEC source: 0001639225-20-000060 · wf-form4_160409251194751.xml · nonDerivative · entry 8 TULLMAN GLEN · CIK 0001213349 · Director · Executive Chairman 10b5-1 filing: Not disclosed Ownership: Indirect · See footnote Disclosed balance after: 35,887 F12 · kind: Represents a pro rata in-kind distribution by 7wire Ventures Fund, L.P. without consideration to its partners. F13 · ownership.nature: The shares are held of record by 7wire Ventures Fund, L.P. The reporting person serves as a Manager of 7wire Management, the Manager of 7wire Ventures Fund, L.P. The reporting person disclaims beneficial ownership of these securities, and this report shall not be deemed an admission that the reporting person is the beneficial owner of the securities for purposes of Section 16 or for any other purpose. Read SEC document
October 29, 2020 Filed Oct 30, 2020 17:15 UTC	Livongo Health, Inc. LVGO · Entity 145566	OtherCommon Stock	37,712	$0.00	$0.00	Disclosure SEC source: 0001639225-20-000060 · wf-form4_160409251194751.xml · nonDerivative · entry 7 TULLMAN GLEN · CIK 0001213349 · Director · Executive Chairman 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 965,574 F11 · kind: Represents the receipt of shares pursuant to pro rata in-kind distributions by 7wire Ventures LLC - Series Livongo D and 7wire Ventures LLC - Series Livongo E. Read SEC document
October 29, 2020 Filed Oct 30, 2020 17:15 UTC	Livongo Health, Inc. LVGO · Entity 145566	OtherCommon Stock	195,277	$0.00	$0.00	Disclosure SEC source: 0001639225-20-000060 · wf-form4_160409251194751.xml · nonDerivative · entry 6 TULLMAN GLEN · CIK 0001213349 · Director · Executive Chairman 10b5-1 filing: Not disclosed Ownership: Indirect · See footnote Disclosed balance after: 0 F9 · kind: Represents a pro rata in-kind distribution by 7wire Ventures LLC - Series Livongo E without consideration to its partners. F10 · ownership.nature: The shares were held of record by 7wire Ventures LLC - Series Livongo E. The reporting person serves as a Manager of 7wire Management, the Manager of 7wire Ventures LLC - Series Livongo E. The reporting person disclaims beneficial ownership of these securities, and this report shall not be deemed an admission that the reporting person is the beneficial owner of the securities for purposes of Section 16 or for any other purpose. Read SEC document
October 29, 2020 Filed Oct 30, 2020 17:15 UTC	Livongo Health, Inc. LVGO · Entity 145566	OtherCommon Stock	176,361	$0.00	$0.00	Disclosure SEC source: 0001639225-20-000060 · wf-form4_160409251194751.xml · nonDerivative · entry 5 TULLMAN GLEN · CIK 0001213349 · Director · Executive Chairman 10b5-1 filing: Not disclosed Ownership: Indirect · See footnote Disclosed balance after: 0 F7 · kind: Represents a pro rata in-kind distribution by 7wire Ventures LLC - Series Livongo D without consideration to its partners. F8 · ownership.nature: The shares were held of record by 7wire Ventures LLC - Series Livongo D. The reporting person serves as a Manager of 7wire Management, the Manager of 7wire Ventures LLC - Series Livongo D. The reporting person disclaims beneficial ownership of these securities, and this report shall not be deemed an admission that the reporting person is the beneficial owner of the securities for purposes of Section 16 or for any other purpose. Read SEC document
October 29, 2020 Filed Oct 30, 2020 17:15 UTC	Livongo Health, Inc. LVGO · Entity 145566	OtherCommon Stock	109,748	$0.00	$0.00	Disclosure SEC source: 0001639225-20-000060 · wf-form4_160409251194751.xml · nonDerivative · entry 4 TULLMAN GLEN · CIK 0001213349 · Director · Executive Chairman 10b5-1 filing: Not disclosed Ownership: Indirect · See footnote Disclosed balance after: 0 F5 · kind: Represents a pro rata in-kind distribution by 7wire Ventures LLC - Series Livongo C without consideration to its partners. F6 · ownership.nature: The shares were held of record by 7wire Ventures LLC - Series Livongo C. The reporting person serves as a Manager of 7wire Management, the Manager of 7wire Ventures LLC - Series Livongo C. The reporting person disclaims beneficial ownership of these securities, and this report shall not be deemed an admission that the reporting person is the beneficial owner of the securities for purposes of Section 16 or for any other purpose. Read SEC document
October 29, 2020 Filed Oct 30, 2020 17:15 UTC	Livongo Health, Inc. LVGO · Entity 145566	OtherCommon Stock	1,185,097	$0.00	$0.00	Disclosure SEC source: 0001639225-20-000060 · wf-form4_160409251194751.xml · nonDerivative · entry 3 TULLMAN GLEN · CIK 0001213349 · Director · Executive Chairman 10b5-1 filing: Not disclosed Ownership: Indirect · See footnote Disclosed balance after: 0 F3 · kind: Represents a pro rata in-kind distribution by 7wire Ventures, LLC - Series EosHealth without consideration to its partners. F4 · ownership.nature: The shares were held of record by 7wire Ventures LLC - Series EosHealth. The reporting person serves as a Manager of 7wire Management, the Manager of 7wire Ventures LLC - Series EosHealth. The reporting person disclaims beneficial ownership of these securities, and this report shall not be deemed an admission that the reporting person is the beneficial owner of the securities for purposes of Section 16 or for any other purpose. Read SEC document
September 14, 2020 Filed Sep 16, 2020 18:10 UTC	Livongo Health, Inc. LVGO · Entity 145566	SaleCommon Stock	23	$124.46	$2,862.58	Disclosure SEC source: 0001209191-20-050760 · doc4.xml · nonDerivative · entry 1 TULLMAN GLEN · CIK 0001213349 · Director · Executive Chairman 10b5-1 filing: Not disclosed Ownership: Indirect · See footnote Disclosed balance after: 976,675 F1 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $124.46 to $124.465, inclusive. The reporting person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price. F2 · ownership.nature: The shares are held of record by 7wire Ventures Fund, L.P., or 7wire LP. The reporting person serves as a Manager of 7wire Management, LLC, or 7wire Management, the Manager of 7wire LP. The reporting person disclaims beneficial ownership of these securities, and this report shall not be deemed an admission that the reporting person is the beneficial owner of the securities for purposes of Section 16 or for any other purpose. Read SEC document
September 11, 2020 Filed Sep 15, 2020 16:50 UTC	Livongo Health, Inc. LVGO · Entity 145566	OtherCommon Stock	21,604	$0.00	$0.00	Disclosure SEC source: 0001209191-20-050485 · doc4.xml · nonDerivative · entry 6 TULLMAN GLEN · CIK 0001213349 · Director · Executive Chairman 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 947,803 F11 · kind: Represents the receipt of shares pursuant to pro rata in-kind distributions by 7wire LP, 7wire Ventures, LLC - Series Livongo D and 7wire Ventures, LLC - Series Livongo E. Read SEC document
September 11, 2020 Filed Sep 15, 2020 16:50 UTC	Livongo Health, Inc. LVGO · Entity 145566	OtherCommon Stock	65,081	$0.00	$0.00	Disclosure SEC source: 0001209191-20-050485 · doc4.xml · nonDerivative · entry 5 TULLMAN GLEN · CIK 0001213349 · Director · Executive Chairman 10b5-1 filing: Not disclosed Ownership: Indirect · See footnote Disclosed balance after: 195,277 F9 · kind: Represents a pro rata in-kind distribution by 7wire Ventures LLC - Series Livongo E without consideration to its partners. F10 · ownership.nature: The shares are held of record by 7wire Ventures LLC - Series Livongo E. The reporting person serves as a Manager of 7wire Management, the Manager of 7wire Ventures LLC - Series Livongo E. The reporting person disclaims beneficial ownership of these securities, and this report shall not be deemed an admission that the reporting person is the beneficial owner of the securities for purposes of Section 16 or for any other purpose. Read SEC document
September 11, 2020 Filed Sep 15, 2020 16:50 UTC	Livongo Health, Inc. LVGO · Entity 145566	OtherCommon Stock	58,773	$0.00	$0.00	Disclosure SEC source: 0001209191-20-050485 · doc4.xml · nonDerivative · entry 4 TULLMAN GLEN · CIK 0001213349 · Director · Executive Chairman 10b5-1 filing: Not disclosed Ownership: Indirect · See footnote Disclosed balance after: 176,361 F7 · kind: Represents a pro rata in-kind distribution by 7wire Ventures LLC - Series Livongo D without consideration to its partners. F8 · ownership.nature: The shares are held of record by 7wire Ventures LLC - Series Livongo D. The reporting person serves as a Manager of 7wire Management, the Manager of 7wire Ventures LLC - Series Livongo D. The reporting person disclaims beneficial ownership of these securities, and this report shall not be deemed an admission that the reporting person is the beneficial owner of the securities for purposes of Section 16 or for any other purpose. Read SEC document
September 11, 2020 Filed Sep 15, 2020 16:50 UTC	Livongo Health, Inc. LVGO · Entity 145566	OtherCommon Stock	36,576	$0.00	$0.00	Disclosure SEC source: 0001209191-20-050485 · doc4.xml · nonDerivative · entry 3 TULLMAN GLEN · CIK 0001213349 · Director · Executive Chairman 10b5-1 filing: Not disclosed Ownership: Indirect · See footnote Disclosed balance after: 109,748 F5 · kind: Represents a pro rata in-kind distribution by 7wire Ventures LLC - Series Livongo C without consideration to its partners. F6 · ownership.nature: The shares are held of record by 7wire Ventures LLC - Series Livongo C. The reporting person serves as a Manager of 7wire Management, the Manager of 7wire Ventures LLC - Series Livongo C. The reporting person disclaims beneficial ownership of these securities, and this report shall not be deemed an admission that the reporting person is the beneficial owner of the securities for purposes of Section 16 or for any other purpose. Read SEC document
September 11, 2020 Filed Sep 15, 2020 16:50 UTC	Livongo Health, Inc. LVGO · Entity 145566	OtherCommon Stock	395,025	$0.00	$0.00	Disclosure SEC source: 0001209191-20-050485 · doc4.xml · nonDerivative · entry 2 TULLMAN GLEN · CIK 0001213349 · Director · Executive Chairman 10b5-1 filing: Not disclosed Ownership: Indirect · See footnote Disclosed balance after: 1,185,097 F3 · kind: Represents a pro rata in-kind distribution by 7wire Ventures, LLC - Series EosHealth without consideration to its partners. F4 · ownership.nature: The shares are held of record by 7wire Ventures LLC-Series EosHealth. The reporting person serves as a Manager of 7wire Management, the Manager of 7wire Ventures LLC-Series EosHealth. The reporting person disclaims beneficial ownership of these securities, and this report shall not be deemed an admission that the reporting person is the beneficial owner of the securities for purposes of Section 16 or for any other purpose. Read SEC document
September 11, 2020 Filed Sep 15, 2020 16:50 UTC	Livongo Health, Inc. LVGO · Entity 145566	OtherCommon Stock	312,511	$0.00	$0.00	Disclosure SEC source: 0001209191-20-050485 · doc4.xml · nonDerivative · entry 1 TULLMAN GLEN · CIK 0001213349 · Director · Executive Chairman 10b5-1 filing: Not disclosed Ownership: Indirect · See footnote Disclosed balance after: 976,698 F1 · kind: Represents a pro rata in-kind distribution by 7wire Ventures Fund, L.P., or 7wire LP, without consideration to its partners. F2 · ownership.nature: The shares are held of record by 7wire LP. The reporting person serves as a Manager of 7wire Management, LLC, or 7wire Management, the Manager of 7wire LP. The reporting person disclaims beneficial ownership of these securities, and this report shall not be deemed an admission that the reporting person is the beneficial owner of the securities for purposes of Section 16 or for any other purpose. Read SEC document
September 11, 2020 Filed Oct 30, 2020 17:15 UTC	Livongo Health, Inc. LVGO · Entity 145566	OtherCommon Stock	12,080	$0.00	$0.00	Disclosure SEC source: 0001639225-20-000060 · wf-form4_160409251194751.xml · nonDerivative · entry 2 TULLMAN GLEN · CIK 0001213349 · Director · Executive Chairman 10b5-1 filing: Not disclosed Ownership: Indirect · See footnote Disclosed balance after: 12,080 F1 · kind: Represents the receipt of shares pursuant to a pro rata in-kind distribution by 7wire Ventures Wanxiang Strategic Fund I, LP. F2 · ownership.nature: The shares are held of record by 7wire Management I, LLC. The reporting person serves as a Manager of 7wire Management, LLC, or 7wire Management, the Manager of 7wire Management I, LLC. The reporting person disclaims beneficial ownership of these securities, and this report shall not be deemed an admission that the reporting person is the beneficial owner of the securities for purposes of Section 16 or for any other purpose. Read SEC document
September 03, 2020 Filed Sep 4, 2020 21:02 UTC	Livongo Health, Inc. LVGO · Entity 145566	Exercise / conversionEmployee Stock Option (right to buy) · Derivative	422,000	$0.00 Strike: $0.74	$0.00	Disclosure SEC source: 0001209191-20-049674 · doc4.xml · derivative · entry 8 TULLMAN GLEN · CIK 0001213349 · Director · Executive Chairman 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 297,954 Underlying: Common Stock · 422,000 shares Expires 2024-02-12 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F8 · derivative.exercise_date: Shares subject to the option are fully vested and immediately exercisable. Read SEC document
September 03, 2020 Filed Sep 4, 2020 21:02 UTC	Livongo Health, Inc. LVGO · Entity 145566	SaleCommon Stock	422,000	$124.50	$52,539,000.00	Disclosure SEC source: 0001209191-20-049674 · doc4.xml · nonDerivative · entry 2 TULLMAN GLEN · CIK 0001213349 · Director · Executive Chairman 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 926,199 F1 · kind: On August 5, 2020, the Issuer entered into an Agreement and Plan of Merger with Teladoc Health, Inc. ("Teladoc") and Tempranillo Merger Sub, Inc., a wholly-owned subsidiary of Teladoc ("Merger Sub"), pursuant to which Merger Sub will merge with and into the Issuer, with the Issuer surviving as a wholly-owned subsidiary of Teladoc (the "Merger"). Pursuant to the terms of the Rule 10b5-1 trading plan adopted by the reporting person on December 13, 2019, as amended and restated (the "Trading Plan"), all sales pursuant to the Trading Plan were automatically suspended following the public announcement of the Merger without any action by the reporting person, and the Trading Plan was subsequently terminated. The number of shares sold and reported on this form is consistent with the number of shares that would have been sold by the reporting person pursuant to the Trading Plan had the Trading Plan not been suspended in connection with the Merger. F2 · kind: In addition, in connection with the Merger the reporting person entered into a voting agreement with Teladoc and certain other stockholders of the Issuer party thereto (the "Voting Agreement"), pursuant to which, subject to certain exceptions, the reporting person agreed to vote all shares of the Issuer's common stock held by the reporting person in favor of the approval of the Merger. The sales reported on this form are expressly permitted and contemplated by the Voting Agreement, which permits the reporting person to sell or transfer a number of shares of the Issuer's common stock equivalent to such number of shares that would have been sold had the Trading Plan remained in effect. Following the sales reported on this form, the reporting person continues to hold over 85% of the shares of the Issuer's common stock and vested stock options directly held immediately prior to such sales. Read SEC document
September 03, 2020 Filed Sep 4, 2020 21:02 UTC	Livongo Health, Inc. LVGO · Entity 145566	Exercise / conversionCommon Stock	422,000	$0.74	$312,280.00	Disclosure SEC source: 0001209191-20-049674 · doc4.xml · nonDerivative · entry 1 TULLMAN GLEN · CIK 0001213349 · Director · Executive Chairman 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 1,348,199 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document
August 26, 2020 Filed Aug 28, 2020 16:04 UTC	Livongo Health, Inc. LVGO · Entity 145566	SaleCommon Stock	2,322	$132.53	$307,734.66	Disclosure SEC source: 0001209191-20-048605 · doc4.xml · nonDerivative · entry 1 TULLMAN GLEN · CIK 0001213349 · Director · Executive Chairman 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 926,199 F1 · kind: The reported shares were sold to satisfy the reporting person's tax obligations in connection with the vesting of restricted stock units. Read SEC document
June 30, 2020 Filed Jul 1, 2020 19:31 UTC	Livongo Health, Inc. LVGO · Entity 145566	SaleCommon Stock	52	$74.76	$3,887.52	Disclosure SEC source: 0001209191-20-039943 · doc4.xml · nonDerivative · entry 1 TULLMAN GLEN · CIK 0001213349 · Director · Executive Chairman 10b5-1 filing: Not disclosed Ownership: Indirect · See footnote Disclosed balance after: 1,289,209 F1 · ownership.nature: The shares are held of record by 7wire Ventures Fund, L.P., or 7wire LP. The reporting person serves as a Manager of 7wire Management, LLC, or 7wire Management, the Manager of 7wire LP. The reporting person disclaims beneficial ownership of these securities, and this report shall not be deemed an admission that the reporting person is the beneficial owner of the securities for purposes of Section 16 or for any other purpose. Read SEC document
June 25, 2020 Filed Jun 29, 2020 21:52 UTC	Livongo Health, Inc. LVGO · Entity 145566	OtherCommon Stock	26,589	$0.00	$0.00	Disclosure SEC source: 0000899243-20-017830 · doc4.xml · nonDerivative · entry 6 TULLMAN GLEN · CIK 0001213349 · Director · Executive Chairman 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 928,521 F11 · kind: Represents the receipt of shares pursuant to pro rata in-kind distributions by 7wire LP, 7wire Ventures, LLC - Series Livongo D and 7wire Ventures, LLC - Series Livongo E. Read SEC document
June 25, 2020 Filed Jun 29, 2020 21:52 UTC	Livongo Health, Inc. LVGO · Entity 145566	OtherCommon Stock	384,629	$0.00	$0.00	Disclosure SEC source: 0000899243-20-017830 · doc4.xml · nonDerivative · entry 5 TULLMAN GLEN · CIK 0001213349 · Director · Executive Chairman 10b5-1 filing: Not disclosed Ownership: Indirect · See footnote Disclosed balance after: 1,289,261 F9 · kind: Represents a pro rata in-kind distribution by 7wire Ventures Fund, L.P., or 7wire LP, without consideration to its partners. F10 · ownership.nature: The shares are held of record by 7wire LP. The reporting person serves as a Manager of 7wire Management, the Manager of 7wire LP. The reporting person disclaims beneficial ownership of these securities, and this report shall not be deemed an admission that the reporting person is the beneficial owner of the securities for purposes of Section 16 or for any other purpose. Read SEC document

Value uses the disclosed total when available, otherwise shares × reported transaction price. It is not an estimate of exercise cash cost or investment performance.